New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: Glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)

Diabetes, Obesity and Metabolism

Volumn 18, Issue 4, 2016, Pages 375-383

  Matsuhisa, M ^a   Koyama, M ^b   Cheng, X ^c   Takahashi, Y ^b   Riddle, M C ^d   Bolli, G B ^e   Hirose, T ^f  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b Sanofi ^*  (Japan)

^c Sanofi Pasteur   (China)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF PERUGIA   (Italy)

^f TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Basal insulin; Glycaemic control; Insulin analogues; Phase III study; Randomised trial; Type 1 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; ANTIDIABETIC AGENT; DELAYED RELEASE FORMULATION; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ALLERGIC REACTION; ARTICLE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEEDING BEHAVIOR; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INJECTION PEN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT CHANGE; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION; FOLLOW UP; HYPERGLYCEMIA; JAPAN; MIDDLE AGED; MULTIDRUG RESISTANCE; RANDOMIZED CONTROLLED TRIAL; RISK; THERAPEUTIC USE;

ADULT; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN DETEMIR; INSULIN GLARGINE; JAPAN; MALE; MIDDLE AGED; RISK;

EID: 84959866323     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12619     Document Type: Article

References (28)

1. American Diabetes Association. Standards of medical care in diabetes - 2015. 7. Approaches to glycemic treatment. Diabetes Care 2015; 38: S41-S48.
2. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 2014; 383: 69-82.
3. Japan Diabetes Society. Treatment guide for diabetes 2013; 2012-2013.
4. Recent product approvals in Japan. Inpharma Weekly 2003; 1411: 21.
5. Kanazawa Y, Igarashi Y, Komiya K et al. Long-term efficacy of insulin glargine after switching from NPH insulin as intensive replacement of basal insulin in Japanese diabetes mellitus. Comparison of efficacy between type 1 and type 2 diabetes (JUN-LAN study 1.2). Endocr J 2007; 54: 975-983.
6. Yamamoto-Honda R, Takahashi Y, Yoshida Y et al. Use of insulin glargine in Japanese patients with type 1 diabetes. Intern Med 2007; 46: 937-943.
7. Chan JC, Gagliardino JJ, Baik SH et al. Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS). Diabetes Care 2009; 32: 227-233.
8. Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care 2013; 36: 2271-2279.
9. Vouri SM, Shaw RF, Waterbury NV, Egge JA, Alexander B. Prevalence of achievement of A1c, blood pressure, and cholesterol (ABC) goal in veterans with diabetes. J Manag Care Pharm 2011; 17: 304-312.
10. Bolli GB, Andreoli AM, Lucidi P. Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era. Diabetes Technol Ther 2011; 13(Suppl. 1): S43-S52.
11. Owens DR, Matfin G, Monnier L. Basal insulin analogues in the management of diabetes mellitus: what progress have we made? Diabetes Metab Res Rev 2014; 30: 104-119.
12. Becker RH, Nowotny I, Teichert L, Bergmann K, Kapitza C. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes Metab 2015; 17: 261-267.
13. -1. Diabetes Care 2015; 38: 637-643.
14. Shiramoto M, Eto T, Irie S et al. Single-dose new 0insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab 2015; 17: 254-260.
15. Bolli GB, Riddle MC, Bergenstal RM et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab 2015; 17: 386-394.
16. Home PD, Bergenstal RM, Bolli GB et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care 2015; 38: 2217-2225.
17. Riddle MC, Bolli GB, Zieman M et al. New insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes using basal and mealtime insulin: glucose and hypoglycemia in a 6-month randomized controlled trial (EDITION I). Diabetes Care 2014; 37: 2755-2762.
18. Terauchi Y, Koyama M, Cheng X, Shimizu S, Hirose T. Glycemic control and hypoglycaemia in Japanese people with type 2 diabetes mellitus receiving new insulin glargine 300 U/mL in combination with OADs (EDITION JP 2). Diabetologia 2014; 57: S401.
19. Yki-Järvinen H, Bergenstal R, Zieman M et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care 2014; 37: 3235-3243.
20. Bergenstal R, Bailey TS, Rodbard D, Guo H, Muehlen-Bartmer I, Ahmann AJ. Insulin glargine 300 U/mL vs 100 U/mL: glucose profiles of morning vs evening injections in adults with T1DM measured with continuous glucose monitoring (CGM). Diabetes Technol Ther 2015; 17: A16-A17.
21. ICH. ICH harmonized tripartite guideline: guideline for good clinical practice E6 (R1), 1996. Available from URL: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. Accessed 19 January 2016.
22. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Ferney-Voltaire: World Medical Association, 2013.
23. ADA Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245-1249.
24. Heller S, Buse J, Fisher M et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1489-1497.
25. Mathieu C, Hollander P, Miranda-Palma B et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013; 98: 1154-1162.
26. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003; 26: 1902-1912.
27. Gerstein HC, Bosch J, Dagenais GR et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-328.
28. Iwamoto Y, Clauson P, Nishida T, Kaku K. Insulin degludec in Japanese patients with type 1 diabetes mellitus: a randomized controlled trial. J Diabetes Invest 2013; 4: 62-68.